Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Aug 5

PMID 34350109

Citations 7

Authors

Shengnan Zhou

Shitao Jiang

Weijie Chen

Haixin Yin

Liangbo Dong

Hao Zhao

Shaoqi Han

Xiaodong He

Affiliations

Soon will be listed here.

Abstract

Background: For this study, we explored the prognostic profiles of biliary neuroendocrine neoplasms (NENs) patients and identified factors related to prognosis. Further, we developed and validated an effective nomogram to predict the overall survival (OS) of individual patients with biliary NENs.

Methods: We included a total of 446 biliary NENs patients from the SEER database. We used Kaplan-Meier curves to determine survival time. We employed univariate and multivariate Cox analyses to estimate hazard ratios to identify prognostic factors. We constructed a predictive nomogram based on the results of the multivariate analyses. In addition, we included 28 biliary NENs cases from our center as an external validation cohort.

Results: The median survival time of biliary NENs from the SEER database was 31 months, and the value of gallbladder NENs (23 months) was significantly shorter than that of the bile duct (45 months) and ampulla of Vater (33.5 months, p=0.023). Multivariate Cox analyses indicated that age, tumor size, pathological classification, SEER stage, and surgery were independent variables associated with survival. The constructed prognostic nomogram demonstrated good calibration and discrimination C-index values of 0.783 and 0.795 in the training and validation dataset, respectively.

Conclusion: Age, tumor size, pathological classification, SEER stage, and surgery were predictors for the survival of biliary NENs. We developed a nomogram that could determine the 3-year and 5-year OS rates. Through validation of our central database, the novel nomogram is a useful tool for clinicians in estimating individual survival among biliary NENs patients.

Citing Articles

Clinical diagnosis and treatment of 37 cases of gallbladder neuroendocrine carcinoma.

Liu F, Miao W, Nan J, Shi Z, Zhang A, Bo Y World J Surg Oncol. 2024; 22(1):157.

PMID: 38877554 PMC: 11177431. DOI: 10.1186/s12957-024-03436-z.

Primary perihilar bile duct neuroendocrine tumor: a case report and review of the literature.

Ai H, Gong T, Ma Y, Ma G, Zhao J, Zhao X Am J Transl Res. 2024; 16(2):531-538.

PMID: 38463593 PMC: 10918117.

Nomograms for Predicting Survival Outcomes in Patients with Neuroendocrine Neoplasms of the Gallbladder Undergoing Primary Tumor Resection: A Population-Based Study.

Zhang Y, Hu G, Fan M, Yao H, Jiang C, Shi H Curr Oncol. 2023; 30(3):2889-2899.

PMID: 36975434 PMC: 10047496. DOI: 10.3390/curroncol30030221.

Neuroendocrine neoplasm of the gallbladder: Clinical features, surgical efficacy, and prognosis.

Wu X, Li B, Hong T, Liu W, He X, Zheng C Cancer Med. 2023; 12(10):11344-11350.

PMID: 36952352 PMC: 10242308. DOI: 10.1002/cam4.5846.

Development and validation of prognostic nomograms in patients with gallbladder mucinous adenocarcinoma: A population-based study.

Xu X, Wang J Front Oncol. 2023; 12:1084445.

PMID: 36591489 PMC: 9795173. DOI: 10.3389/fonc.2022.1084445.

References

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

Kurita Y, Hara K, Kuwahara T, Mizuno N, Okuno N, Haba S . Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J Gastroenterol. 2019; 55(5):543-552. DOI: 10.1007/s00535-019-01655-w. View

Centonze G, Lagano V, Sabella G, Mangogna A, Garzone G, Filugelli M . Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. J Clin Med. 2021; 10(8). PMC: 8072982. DOI: 10.3390/jcm10081741. View

Mafficini A, Scarpa A . Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev. 2019; 40(2):506-536. PMC: 6534496. DOI: 10.1210/er.2018-00160. View

Zhang S, Tong Y, Zhang X, Zhang Y, Xu X, Xiao A . A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. J Cancer. 2019; 10(24):5944-5954. PMC: 6856574. DOI: 10.7150/jca.35785. View

Basu S, Parghane R, Kamaldeep , Chakrabarty S . Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Semin Nucl Med. 2020; 50(5):447-464. DOI: 10.1053/j.semnuclmed.2020.05.004. View

Modlin I, Gustafsson B, Pavel M, Svejda B, Lawrence B, Kidd M . A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology. 2010; 92(3):143-57. DOI: 10.1159/000319784. View

Jeong H, Shin J, Jeong J, Kim K, Hong S, Kim Y . Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open. 2021; 6(3):100119. PMC: 8099746. DOI: 10.1016/j.esmoop.2021.100119. View

Ellison T, Wolfgang C, Shi C, Cameron J, Murakami P, Mun L . A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2013; 259(2):204-12. PMC: 4048026. DOI: 10.1097/SLA.0b013e31828f3174. View

10.

Zheng Z, Chen C, Li B, Liu H, Zhou L, Zhang H . Biliary Neuroendocrine Neoplasms: Clinical Profiles, Management, and Analysis of Prognostic Factors. Front Oncol. 2019; 9:38. PMC: 6370735. DOI: 10.3389/fonc.2019.00038. View

11.

Pulvirenti A, Javed A, Landoni L, Jamieson N, Chou J, Miotto M . Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. Ann Surg. 2019; 274(6):1051-1057. PMC: 8557638. DOI: 10.1097/SLA.0000000000003579. View

12.

Yang M, Zhang Y, Zeng L, Ke N, Tan C, Tian B . Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large.... Pancreas. 2019; 48(5):613-621. DOI: 10.1097/MPA.0000000000001305. View

13.

Lee K, Cho J, Lee S, Lee K, Park B, Kyu Lee J . Clinicopathological characteristics of biliary neuroendocrine neoplasms: a multicenter study. Scand J Gastroenterol. 2016; 52(4):437-441. DOI: 10.1080/00365521.2016.1261938. View

14.

Hosoda K, Kobayashi A, Shimizu A, Kitagawa N, Ito T, Yamada A . Neuroendocrine tumor of the common bile duct. Surgery. 2016; 160(2):525-6. DOI: 10.1016/j.surg.2016.01.001. View

15.

Rindi G, Wiedenmann B . Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol. 2020; 16(10):590-607. DOI: 10.1038/s41574-020-0391-3. View

16.

Hong S, Kim M, Pi D, Jo D, Yu E, Ro J . Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance. Hum Pathol. 2005; 36(7):732-40. DOI: 10.1016/j.humpath.2005.05.002. View

17.

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

18.

Randle R, Ahmed S, Newman N, Clark C . Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study. J Gastrointest Surg. 2013; 18(2):354-62. DOI: 10.1007/s11605-013-2365-4. View

19.

Kloppel G, Rindi G, Perren A, Komminoth P, Klimstra D . The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010; 456(6):595-7. DOI: 10.1007/s00428-010-0924-6. View

20.

Kim J, Lee W, Lee S, Lee K, Ryu J, Kim Y . Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. Dig Liver Dis. 2011; 43(12):965-70. DOI: 10.1016/j.dld.2011.07.010. View